Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387110 · ClinicalTrials.gov registry record
Ocrelizumab in Breastmilk
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 30
- Enrollment target
NCT04387110 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT04387110 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The goal of the current project is to measure the levels of ocrelizumab in the breastmilk of women with multiple sclerosis (MS) and clinically isolated syndrome (CIS) who are postpartum, and to collect information on 12-month infant development outcomes (length, weight, head circumference, infections) in their offspring. This study will fill a significant unmet need as many women with MS at high risk for postpartum relapses are not effectively treated for their MS in the postpartum period due to lack of information about the presence, concentration and effects of medications in breastmilk.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2022-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387110
The ClinicalTrials.gov registry entry for NCT04387110 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT04387110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04387110 about?
NCT04387110 is a clinical study titled "Ocrelizumab in Breastmilk". The goal of the current project is to measure the levels of ocrelizumab in the breastmilk of women with multiple sclerosis (MS) and clinically isolated syndrome (CIS) who are postpartum, and to collect information on 12-month infant development outcomes (length, weight, head circumference, infection...
What is the current status of trial NCT04387110?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2020-08-07. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04387110?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT04387110?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.